Dr. Jeffrey Weber on the Keys to Targeted Treatments

November 7, 2015
Jeffrey Weber, MD, PhD

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, discusses keys to targeted therapies for melanoma. These keys lie in BRAF and MEK inhibitors and combining those drugs with immunologic therapies.

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, discusses keys to targeted therapies for melanoma. These keys lie in BRAF and MEK inhibitors and combining those drugs with immunologic therapies.

Weber touches on several new combinations, adding that medical professionals have more treatment options than they ever have before. Weber said in order to prove superiority for these treatments over older therapies, several studies need to be conducted.